ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization
Phase 1
Completed
- Conditions
- Prevention of COVID-19
- Interventions
- Biological: Recombinant novel coronavirus vaccine (CHO cells)
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05198102
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
Phase 1
Completed
- Conditions
- Prevention of COVID-19
- Interventions
- Biological: Recombinant novel coronavirus vaccine (CHO cells)
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05198063
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention Preventive Medicine Clinic, Changsha, Hunan, China
Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)
Phase 3
- Conditions
- Coronavirus Disease 2019
- Interventions
- Biological: Recombinant novel coronavirus vaccine (CHO cell)
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05128643
- Locations
- 🇨🇳
Hunan Center for Disease Control and Prevention, Changsha, Hunan, China
Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell)
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Recombinant new coronavirus vaccine (CHO cell)
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05109598
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Phase 3
Completed
- Conditions
- Coronavirus Disease 2019
- Interventions
- Biological: Tetravalent influenza virus lysis vaccineBiological: Recombinant new coronavirus vaccine (CHO cell) group
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 299
- Registration Number
- NCT05107375
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)
Phase 3
- Conditions
- Coronavirus Disease 2019
- Interventions
- Biological: Recombinant new coronavirus vaccine (CHO cell) group
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 1680
- Registration Number
- NCT05091411
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity
Not Applicable
Completed
- Conditions
- Coronavirus Disease 2019
- Interventions
- Biological: Recombinant new coronavirus vaccine (CHO cell) group
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05089045
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)
Phase 1
Completed
- Conditions
- Coronavirus
- Interventions
- Biological: Recombinant new coronavirus vaccine (CHO cell) groupBiological: Recombinant new coronavirus vaccine (CHO cells) placebo group
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT04961359
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)
Phase 3
Active, not recruiting
- Conditions
- Rabies Vaccine Adverse ReactionSafety and Efficacy
- Interventions
- Biological: Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose programBiological: Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose programBiological: Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose programBiological: Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 2480
- Registration Number
- NCT04852068
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19
Phase 3
- Conditions
- Safety and EfficacyPrevention of COVID-19
- Interventions
- Biological: Recombinant new coronavirus vaccine (CHO cell) groupBiological: Recombinant new coronavirus vaccine (CHO cells) placebo group
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 28904
- Registration Number
- NCT04646590
- Locations
- 🇺🇿
GUVD Poliklinika, Tashkent, Uzbekistan
🇨🇳Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
🇮🇩Fkui-Rscm, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
© Copyright 2025. All Rights Reserved by MedPath